Sinonasal Mucosal Melanoma: A 13-Year Experience at a Single Institution

ABSTRACT

Objective: Report the experience of the Karmanos Cancer Institute with sinonasal mucosal melanoma (SNMM) in patients diagnosed between 1995 and 2007. Results: Eighteen patients, ages 31 to 85 (mean, 67), whose most common presenting symptoms included epistaxis and facial pressure. Most common anatomic locations were the maxillary sinus and nasal cavity. Seventy-two percent presented with tumors extending to the skull base, frontal sinus, orbit, or cranium. Tumor size ranged from 0.3 cm to 5.3 cm. Most common surgical procedure was medial maxillectomy (12 patients). Eight patients received chemotherapy, ten received radiotherapy and six received both. One third of patients received interferon-α. Median recurrence-free survival (RFS) was 14.4 months, with a 1-year RFS rate of 55%. Median overall survival (OS) was 19.3 months with a 1-year OS rate of 60% and a 2-year OS rate of 42%. The 5-year OS rate was 34%. Conclusion: SNMM remains a disease that has eluded breakthroughs in treatment. Patients are typically treated with wide local resection; however unique to our institution was the frequent use of interferon and chemoradiation. Further research in adjuvant therapies will be necessary to improve outcomes.

Melanoma - sinus - nasal cavity - sinonasal mucosal melanoma

REFERENCES

• 1 Thompson A C, Morgan D A, Bradley P J. Malignant melanoma of the nasal cavity and paranasal sinuses.  Clin Otolaryngol. 1993;  18 34-36
• 2 Conley J J, Ackerman A B. Melanoma of the Head and Neck. 1st ed. New York; Georg Thieme Verlag 1990: 154-178
• 3 Thompson L DR, Wienke J A, Miettinen M. Sinonasal tract and nasopharyngeal melanomas: a clinicopathologic study of 115 cases with a proposed staging system.  Am J Surg Pathol. 2003;  27(5) 594-611
• 4 Cheng Y F, Lai C C, Ho C Y, Shu C H, Lin C Z. Toward a better understanding of sinonasal mucosal melanoma: clinical review of 23 cases.  J Chin Med Assoc. 2007;  70(1) 24-29
• 5 Lee E. Statistical Methods for Survival Data Analysis. 3rd ed. Hoboken, New Jersey; Wiley & Sons, Inc. 2003: 76-91
• 6 Manolidis S, Donald P J. Malignant mucosal melanoma of the head and neck: review of the literature and a report of 14 patients.  Cancer. 1997;  80(8) 1373-1386
• 7 Holmstrom M, Lund V J. Malignant melanomas of the nasal cavity after occupational exposure to formaldehyde.  Br J Ind Med. 1991;  48(1) 9-11
• 8 Barrett A W, Scully C. Human oral mucosal melanocytes: a review.  J Oral Pathol Med. 1994;  23 97-103
• 9 Wick M R, Stanley S J, Swanson P E. Immunohistochemical diagnosis of sinonasal melanoma, carcinoma, and neuroblastoma with monoclonal antibodies HMB-45 and anti-synaptophysin.  Arch Pathol Lab Med. 1988;  112 616-620
• 10 Koops H S, Vaglini M, Suciu S et al.. Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, and the North American Perfusion Group Southwest Oncology Group-8593.  J Clin Oncol. 1998;  16(9) 2906-2912
• 11 Kirkwood J M, Strawderman M H, Ernstoff M S et al.. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.  J Clin Oncol. 1996;  14(1) 7-17
• 12 Kirkwood J M, Ibrahim J, Lawson D H et al.. High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696.  J Clin Oncol. 2001;  19(5) 1430-1436
• 13 Hancock B W, Wheatley K, Harris S et al.. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study–United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon alfa-2a in high-risk resected malignant melanoma.  J Clin Oncol. 2004;  22(1) 53-61
• 14 Kingdom T T, Kaplan M. Mucosal melanoma of the nasal cavity and paranasal sinuses.  Head Neck. 1995;  17(3) 184-189
• 15 Gilligan D, Slevin N J. Radical radiotherapy for 23 cases of mucosal melanoma in the nasal cavity and paranasal sinuses.  Br J Radiol. 1991;  64 1147-1150
• 16 Lund V J, Howard D J, Harding L, Wei W I. Management options and survival in malignant melanoma of the sinonasal mucosa.  Laryngoscope. 1999;  109(2 Pt 1) 208-211
• 17 Brandwein M S, Rothstein A, Lawson W, Bodian C, Urken M L. Sinonasal melanoma: a clinicopathologic study of 25 cases and literature meta-analysis.  Arch Otolaryngol Head Neck Surg. 1997;  123(3) 290-296